2 completed, 2 recruiting, 1 active not recruiting. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Recruiting 2, Active not recruiting 1 |
Follow sparsentan: new trials by email Literature Review of sparsentan trials Research Report on sparsentan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN Sparsentan - Immunoglobulin A Nephropathy | Phase 2 | Completed | Travere Therapeutics, Inc. | 48 | 2023-05-19 | 2025-11-20 |
| ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC) Sparsentan - ANCA Associated Vasculitis, Cardiovascular Diseases | Phase 2 | Active not recruiting | University of Edinburgh | 32 | 2022-12-08 | 2026-08-26 |
| Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases Sparsentan - Focal Segmental Glomerulosclerosis, Minimal Change Disease | Phase 2 | Recruiting | Travere Therapeutics, Inc. | 67 | 2021-08-12 | 2026-05-12 |
| A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy Sparsentan - Immunoglobulin A Nephropathy, Kidney Diseases | Phase 2 | Recruiting | University of Leicester | 24 | 2020-12-10 | 2026-06-03 |
| Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis RE-021 (Sparsentan), Irbesartan - Focal Segmental Glomerulosclerosis | Phase 2 | Completed | Travere Therapeutics, Inc. | 109 | 2014-03-01 | 2025-05-15 |
Glomerulonephritis, IGA (3) · Glomerulosclerosis, Focal Segmental (2) · Kidney Diseases (2) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1) · Autoimmune Diseases (1) · Cardiovascular Diseases (1) · Glomerulonephritis (1) · IgA Vasculitis (1) · Immune System Diseases (1) · Macular dystrophy, corneal type 1 (1) · Nephritis, Hereditary (1) · Nephrosis, Lipoid (1) · Nephrotic Syndrome (1)
Travere Therapeutics, Inc. (3) · University of Edinburgh (1) · University of Leicester (1)
United Kingdom (3) · United States (3) · Italy (2) · Czechia (1) · Germany (1) · Hong Kong (1) · Netherlands (1) · Poland (1) · Spain (1) · Sweden (1)
Radko Komers, MD, PhD (2) · Chee Kay Cheung, MBChB PhD (1) · Howard Trachtman, M.D. (1) · Neeraj Dhaun (1)
PMID 30361325, PMID 35224732, PMID 36657027, PMID 38724717, PMID 38831932, PMID 40337980, PMID 40938675, PMID 42384439
2018 (1)